Criteria for High Risk Smoldering Myeloma. Also see Revised Mayo 20-2-20 risk stratification
(20%BMPC, 2g/dL M protein, 20 FLC ratio) #myelomaVR @MayoMyeloma
@mtmdphd@MyelomaTeacher https://t.co/QtiTW3Njgh
Very nice analysis by the Wash U group showing persistence of disease-associated mutations at day +30 post allogeneic transplantation are predictive of PFS and relapse risk in MDS patients. #bmtsm#leusm
https://t.co/hWInIxVlWe
Big news just in...Combo of PD-L1 inh. Avelumab + TKI axitinib is the 1st + IO/TKI PIII that met PFS 1*endpoint irrespective of PD-L1! @pfizer @DanaFarber @kcCURE @IKCCorg @KidneyCancer Great day for RCC patients! https://t.co/sb8SmzJA6w
Our current approach to #cancer treatment, despite some modest improvements, is still far from precise. @LizSzabo@KHNews gets real & reminds us of the long road ahead. https://t.co/yCVT2W9dmn @nytopinion
He is analytical and reflective, a lofty dreamer. She will joke and kvetch and needle. Together they have made a life together — and together they are confronting the unthinkable. https://t.co/WtmLPAMiCz
Provocative article @TheLancetOncol RCTs are being done with the aim of gaining regulatory authorisation, while testing trivial clinical questions. Hence the importance of academics trials https://t.co/GRILp8582V
Announcing the 2018 Class of PCF Young Investigators! We are so proud to fund these amazing early career scientists who have dedicated their careers to ending #ProstateCancer!
#PCFfunded@PCFnews@manyvscancer
https://t.co/54LDyP2xCp
The #1 supplement—fish oil—taken by tens of millions Americans for billions of dollars/yr. And the latest trial to debunk any value in them.
https://t.co/ULsTjDfcpu @NEJM#ESCCongress
McCain said in a statement that he has surpassed expectations for his survival since his diagnosis. "But the progress of disease and the inexorable advance of age render their verdict," and the senator has decided to end medical treatment. https://t.co/mrtbnZ1d0L
SOLAR-1 Trial (PI3-k Inh. Alpelisib in Metastatic Breast Cancer) met primary endpont of PFS. Key things to look when data is reported(likely #ESMO18 ): 1. Toxicity profile 2. Magnitude of diff. in PFS 3. Efficacy in CDK4/6 tx patients 4. PI3k test profile https://t.co/ly1UvN9KFc
Our work on Steroids and PD-(L)1 Blockade.
This is not randomized data, and pts that need steroids have probably a poorer prognosis (because of symptomatic brain or bone mets, recent radiotherapy...).
Pts should receive IO when indicated, even w steroids. https://t.co/HKlei2hLew